AbbVie Inc. (ABBV)
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's newer drugs are growing fast enough to more than replace Humira revenue. The hardest part of the transition appears to be behind it.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.
5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income
Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by comparison.
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
AbbVie (ABBV) reached $281.04 at the closing of the latest trading day, reflecting a +1.65% change compared to its last close.
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the immunology market.
Prediction: AbbVie's Next Billion-Dollar Opportunity Is Taking Shape
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall Street divided between a $297 bull case and
5 Dividend Stocks for Retirees Who Want More Than Just a Big Yield
A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, and not every high-yielder clears it.
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction.
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
ABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.
AI ETFs: Beyond Chips & Hyperscalers
While AI investing initially centered on hyperscalers and chips, the opportunity has been broadening as infrastructure grows. Opportunities are moving further down and across the supply chain — into memory, data center power, components, and robotics.
